Mark Kendall (engineer)

Mark A. F. Kendall (BE PhD FRSA FTSE) (born 1972) is an Australian biomedical engineer, inventor, scientist and entrepreneur.

Mark Kendall
Born (1972-04-16) 16 April 1972
NationalityAustralian
OccupationBiomedical engineer
EmployerAustralian National University
Known forBiomedical invention

He is Founder and CEO of WearOptimo Pty Ltd[1] and the Vice-Chancellor's Entrepreneurial Professor at the Australian National University[2].

Kendall was formerly the Professor of Biomedical Engineering at the University of Queensland, where he led a team at the Australian Institute for Bioengineering and Nanotechnology. He was Founder, CTO and a Director of Vaxxas. Prior to this, in the UK, he was a University Research Lecturer at the University of Oxford and a Lecturer at Magdalen College, Oxford. Whilst at Oxford, Kendall was Associate Director of the PowderJect Research Centre for Gene and Drug Delivery.

Kendall serves at the co-chair of the $150 million Australian Stem Cell Therapies Mission[3] and on the World Economic Forum Global Future Council on Biotechnology[4].

Kendall is widely regarded as a work leader in biotechnology, particularly in the field of medical devices for global impact. He has invented more than 160 patents (including territories), published in excess of 300 papers, licensed his technologies seven times (including to Merck & Co.) and partnered globally, including with the World Health Organization, and the Bill & Melinda Gates Foundation[5]. The biotech enterprises he has founded or made significant contribution to have generated in the region of $2 billion Aus in value.

Kendall's contributions to innovation in global healthcare has been recognised with more than forty awards. These include recent elections as:

• World Economic Forum Technology Pioneer (2015)[6].

• Fellow of ATSE; Australian Academy of Technological Sciences and Engineering (2017)[7].

• Fellow of the Royal Society for the encouragement of Arts, Manufacture and Commerce (now the RSA), UK; (2017).

Kendall is a CSL Young Florey Medallist[8] and Rolex Laureate[9][10][11].

Kendall's work regularly features in international media, including on the National Geographic Channel[12].

Kendall's TedGlobal talk has been viewed more than a million times[13].

https://www.ted.com/speakers/mark_kendall

Background

Kendall was born on April 16th 1972.[14] He received his Bachelors of Engineering (Hons I, 1993) and PhD (1998) from the University of Queensland[15].

In 1998, Kendall moved to the UK to take up a position in the Department of Engineering Science at the University of Oxford (1998-2006). He has subsequently held positions at the University of Queensland (2006-2018) and at the Australian National University (2018 - Present).


Contributions to Biotechnology

Kendall has over 160 patent applications of which, 128 have been granted to date. He has authored more than 300 refereed papers.

At the University of Oxford[15] (1998-2006) Kendall developed a biolistic technique for the delivery of vaccines directly into the skin without the use of needles.

At the University of Queensland (2006-2018) Kendall invented the Nanopatch[16][17] for needle-free delivery of vaccines[18][19].

At WearOptimo[20] and the Australian National University[21] (2018 to present), Kendall has invented the Microwearable™ [22][23] sensor for personalised medicine.

During his career, Kendall has collaborated with major global health partners including the Bill & Melinda Gates Foundation [24], World Health Organization[25][26] and Merck & Co.[27].

He is an Australian Government Academy of Science Covid-19 Expert [28].

Selected Awards, Honours and Prizes
  • Elected to the World Economic Forum Global Future Council on Biotechnology (2019 to present)[29].
  • Elected Fellow of the Australian Academy of Technology and Engineering ATSE (2017)[30].
  • Elected Fellow of the Royal Society for the encouragement of Arts, Manufacture and Commerce (now the RSA), UK (2017).
  • Elected to the World Economic Forum Global Future Council on Entrepreneurship and Innovation (2016-2018).
  • Dr John Dixon Hughes Medal for Medical Research Innovation (2016)[34].
  • World Economic Forum Technology Pioneer (2015)[35].
  • Rolex Laureate Award for Enterprise (2012)[36] for his "pioneering efforts to expand knowledge and improve human life" [37].
  • 2011 Australian Innovation Challenge winner[38].
  • 2011 Eureka Prize for Interdisciplinary Research[39].
  • 2010 Merck Translational Research Excellence Commercialisation Award[40].
  • 2005 Best Medical Innovation Award (Popular Science magazine).
  • Younger Engineer of Great Britain (2004).

Contributions to biotech companies

As Associate Director of the Oxford University PowderJect Research Centre (2000-2006), Kendall advanced biolistics technology, commercialised with PowderJect, purchased by Chiron (later Novartis) in 2003; and then with PowderMed, purchased by Pfizer in 2006.

Kendall founded Vaxxas in 2011 to advance his Nanopatch[41] technology for global impact, securing more than $40 million of investment, in the series A ($15m) [42] and B (in excess of $25m) rounds[43]. The Nanopatch technology has been licensed to Merck & Co. He served as the Vaxxas Chief Technology Officer, Director, and Chair of the Vaxxas Advisory Board (2011-2015).

In 2018, Kendall founded WearOptimo[44] where he serves as CEO and is driving forward his Microwearable™ sensor technology for precision medicine.

References
  1. "Home | WearOptimo | Microwearable devices | Australia". WearOptimo / to edit. Retrieved 8 June 2020.
  2. "ANU welcomes funding for wearable medical technology". ANU. 16 May 2018. Retrieved 8 June 2020.
  3. Hunt, Greg (13 March 2019). "Australian Stem Cell Therapies Mission". Retrieved 8 June 2020.
  4. WEF. "Future of Biotechnology". World Economic Forum. Retrieved 8 June 2020.
  5. "After 160 years, it's time to move on from the needle and syringe". www.scienceinpublic.com.au. Retrieved 8 June 2020.
  6. "Authors". World Economic Forum. Retrieved 8 June 2020.
  7. "Mark Kendall elected as a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE)". CBNS. 17 October 2017. Retrieved 8 June 2020.
  8. Australian Institute of, Policy and Science. "Young Florey Medal". Retrieved 9 June 2020.
  9. "Rolex Awards for Enterprise", Wikipedia, 14 March 2020, retrieved 8 June 2020
  10. "Fear of Needles? There's New Tech on the Way". National Geographic News. 14 November 2016. Retrieved 8 June 2020.
  11. "5 Times Rolex Helped to Make the World a Better Place". Time and Tide Watches. 27 September 2016. Retrieved 8 June 2020.
  12. "Fear of Needles? There's New Tech on the Way". National Geographic News. 14 November 2016. Retrieved 10 June 2020.
  13. Kendall, Mark. "Mark Kendall | Speaker | TED". www.ted.com. Retrieved 8 June 2020.
  14. "Mark Kendall: Profile". Rolex Awards for Enterprise. Retrieved 10 June 2016.
  15. Scott, Leisa (30 November 2013). "Professor Mark Kendall, 41, biomedical engineer/inventor". The Courier-Mail. Retrieved 10 June 2016.
  16. Council, Australian Research (5 June 2018). "Nanopatch—Revolutionising treatment of disease across the globe". www.arc.gov.au. Retrieved 10 June 2020.
  17. "UQ technology with the power to revolutionise global vaccine delivery". UniQuest. Retrieved 10 June 2020.
  18. Vidal, John (26 December 2012). "Vaccine patch offers pain-free way to stop disease in Papua New Guinea | John Vidal". The Guardian. ISSN 0261-3077. Retrieved 10 June 2020.
  19. ""Nanopatch" Administers Vaccines Painlessly". National Geographic Society Newsroom. 26 November 2012. Retrieved 10 June 2020.
  20. "About | WearOptimo | Established by Professor Mark Kendall | Brisbane Australia". WearOptimo / to edit. Retrieved 9 June 2020.
  21. "WearOptimo and ANU: towards a healthcare future within the fourth industrial revolution". ANU. 2 October 2018. Retrieved 8 June 2020.
  22. "WearOptimo headquarters open in Brisbane". ANU. 29 March 2019. Retrieved 8 June 2020.
  23. "Our Tech | WearOptimo | Microwearable devises | Australia". WearOptimo / to edit. Retrieved 9 June 2020.
  24. "Nanopatch Delivery of DNA-Based Malaria Vaccines to Skin: Precisely Targeting the Skin Immune System for Radically Improved Vaccines | Grand Challenges". gcgh.grandchallenges.org. Retrieved 9 June 2020.
  25. "Nanopatch polio vaccine delivers". ScienceDaily. Retrieved 9 June 2020.
  26. "Nanopatch creator Mark Kendall". Science Meets Business. 24 April 2017. Retrieved 9 June 2020.
  27. Council, Australian Research (19 July 2018). "ARC Future Fellow pioneers needle-free immunisation for the world". www.arc.gov.au. Retrieved 9 June 2020.
  28. "Expert - Mark Kendall | Australian Academy of Science". www.science.org.au. Retrieved 8 June 2020.
  29. "The Future of Biotechnology". World Economic Forum. Retrieved 10 June 2020.
  30. "Mark Kendall elected as a Fellow of the Australian Academy of Technological Sciences and Engineering (ATSE)". CBNS. 17 October 2017. Retrieved 8 June 2020.
  31. "Professor Mark Kendall wins the 2016 CSL Young Florey Medal". CBNS. 11 November 2016. Retrieved 10 June 2020.
  32. "2016 – Professor Mark Kendall – AIPS". Retrieved 10 June 2020.
  33. "Media Kit – 2016 CSL Young Florey Medal". www.scienceinpublic.com.au. Retrieved 10 June 2020.
  34. "Previous Medal Winners - NFMRINFMRI". Retrieved 10 June 2020.
  35. "4 things Australia needs to know about innovation". World Economic Forum. Retrieved 10 June 2020.
  36. "Rolex Awards for Enterprise", Wikipedia, 14 March 2020, retrieved 8 June 2020
  37. "Researchers: Professor Mark Kendall". Australian Institute for Bioengineering and Nanotechnology. Retrieved 10 June 2016.
  38. Council, Australian Research (19 July 2018). "ARC Future Fellow pioneers needle-free immunisation for the world". www.arc.gov.au. Retrieved 10 June 2020.
  39. Council, Australian Research (19 July 2018). "ARC Future Fellow pioneers needle-free immunisation for the world". www.arc.gov.au. Retrieved 10 June 2020.
  40. "Nanotechnology Now - Press Release: Needle-free vaccine technology a step closer to clinical trials". www.nanotech-now.com. Retrieved 10 June 2020.
  41. Council, Australian Research (5 June 2018). "Nanopatch—Revolutionising treatment of disease across the globe". www.arc.gov.au. Retrieved 10 June 2020.
  42. Queensl, The University of; Lucia, Australia Brisbane St; Gatton, QLD 4072 +61 7 3365 1111 Other Campuses: UQ; Maps, UQ Herston; Queensl, Directions © 2020 The University of. "New vaccine delivery company starts with AUD15 million investment". UQ News. Retrieved 9 June 2020.
  43. Queensl, The University of; Lucia, Australia Brisbane St; Gatton, QLD 4072 +61 7 3365 1111 Other Campuses: UQ; Maps, UQ Herston; Queensl, Directions © 2020 The University of. "Nanopatch vaccine technology company attracts $25 million". UQ News. Retrieved 8 June 2020.
  44. "Home | WearOptimo | Microwearable devices | Australia". WearOptimo / to edit. Retrieved 10 June 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.